| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement
|
|
|
2015
|
|
12 |
p. 1237-1239
|
artikel
|
| 2 |
Acknowledgement
|
|
|
2006
|
|
12 |
p. 1169-1171
|
artikel
|
| 3 |
Acknowledgement
|
|
|
2012
|
|
12 |
p. 1097-1099
|
artikel
|
| 4 |
Acknowledgement
|
|
|
2007
|
|
12 |
p. 991-993
|
artikel
|
| 5 |
Acknowledgement
|
|
|
|
|
12 |
p. 1097-1099
|
artikel
|
| 6 |
Acknowledgements
|
|
|
2014
|
|
12 |
p. 1147-1150
|
artikel
|
| 7 |
Acknowledgement to Referees
|
|
|
2016
|
|
12 |
p. 1191-1193
|
artikel
|
| 8 |
Acknowledgement to Referees
|
|
|
2017
|
|
12 |
p. 1191-1193
|
artikel
|
| 9 |
Acknowledgement to Referees
|
|
|
|
|
12 |
p. 1413-1415
|
artikel
|
| 10 |
Acknowledgement to Referees
|
|
|
|
|
12 |
p. 1279-1281
|
artikel
|
| 11 |
Acknowledgments
|
|
|
2013
|
|
12 |
p. 1083-1085
|
artikel
|
| 12 |
Acknowledgment to Referees
|
|
|
2018
|
|
12 |
p. 1391-1393
|
artikel
|
| 13 |
A Closer Look at Decision and Analyst Error by Including Nonlinearities in Discrete Choice Models: Implications on Willingness-to-Pay Estimates Derived from Discrete Choice Data in Healthcare
|
Bekker-Grob, Esther W. de
|
|
2013
|
|
12 |
p. 1169-1183
|
artikel
|
| 14 |
A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis
|
Djalalov, Sandjar
|
|
|
|
12 |
p. 1525-1536
|
artikel
|
| 15 |
A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy
|
O’Connor, Alec B.
|
|
2008
|
|
12 |
p. 1045-1064
|
artikel
|
| 16 |
A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials
|
Faria, Rita
|
|
2014
|
|
12 |
p. 1157-1170
|
artikel
|
| 17 |
A Practical Guide to Modeling and Conducting a Cost-Effectiveness Analysis of Companion Biomarker Tests for Targeted Therapies Using R: Tutorial Paper
|
Seo, Mikyung Kelly
|
|
|
|
12 |
p. 1373-1381
|
artikel
|
| 18 |
A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States
|
Mavranezouli, Ifigeneia
|
|
2010
|
|
12 |
p. 1109-1121
|
artikel
|
| 19 |
A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments
|
Messali, Andrew
|
|
2014
|
|
12 |
p. 1201-1212
|
artikel
|
| 20 |
A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions
|
Elliott, Rachel A.
|
|
2014
|
|
12 |
p. 1185-1199
|
artikel
|
| 21 |
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies
|
Marshall, Deborah A.
|
|
|
|
12 |
p. 1563-1588
|
artikel
|
| 22 |
Assessing Generalisability in Model-Based Economic Evaluation Studies
|
Urdahl, Hege
|
|
2006
|
|
12 |
p. 1181-1197
|
artikel
|
| 23 |
Assessing Technologies for COVID-19: What are the Challenges for Health Technology Assessment Agencies? Findings From a Survey and Roundtable Workshop
|
Elvidge, Jamie
|
|
|
|
12 |
p. 1455-1463
|
artikel
|
| 24 |
Assessing the Cost Effectiveness of Pre-Exposure Prophylaxis for HIV Prevention in the US
|
Hellinger, Fred J.
|
|
2013
|
|
12 |
p. 1091-1104
|
artikel
|
| 25 |
Assessing the Value of Treatment to Address Various Symptoms Associated with Multiple Sclerosis: Results from a Contingent Valuation Study
|
Lin, Pei-Jung
|
|
2016
|
|
12 |
p. 1255-1265
|
artikel
|
| 26 |
Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies
|
Kapetanakis, Venediktos
|
|
|
|
12 |
p. 1537-1551
|
artikel
|
| 27 |
Association of Co-Morbidities with Prescribing Patterns and Cost Savings
|
Yu, Wei
|
|
2006
|
|
12 |
p. 1233-1248
|
artikel
|
| 28 |
A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia
|
Agrawal, Rumjhum
|
|
|
|
12 |
p. 1159-1186
|
artikel
|
| 29 |
A Systematic Review and Critical Assessment of Health State Utilities
|
Doyle, Scott
|
|
2012
|
|
12 |
p. 1133-1143
|
artikel
|
| 30 |
A Systematic Review and Critical Assessment of Health State Utilities
|
Doyle, Scott
|
|
|
|
12 |
p. 1133-1143
|
artikel
|
| 31 |
Atorvastatin
|
Plosker, Greg L.
|
|
2007
|
|
12 |
p. 1031-1053
|
artikel
|
| 32 |
Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
|
Newall, A. T.
|
|
2014
|
|
12 |
p. 1247
|
artikel
|
| 33 |
Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
|
Gauthier, Aline
|
|
2009
|
|
12 |
p. 1017-1029
|
artikel
|
| 34 |
Bevacizumab for Metastatic Colorectal Cancer
|
Whyte, Sophie
|
|
2012
|
|
12 |
p. 1119-1132
|
artikel
|
| 35 |
Bevacizumab for Metastatic Colorectal Cancer
|
Whyte, Sophie
|
|
|
|
12 |
p. 1119-1132
|
artikel
|
| 36 |
Candesartan Cilexetil
|
Plosker, Greg L.
|
|
2006
|
|
12 |
p. 1249-1272
|
artikel
|
| 37 |
“Can We Declare Victory and Move On?” The Case Against Funding Burden-of-Disease Studies
|
Kymes, Steven
|
|
2014
|
|
12 |
p. 1153-1155
|
artikel
|
| 38 |
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom
|
Gordon, Jason
|
|
|
|
12 |
p. 1657-1673
|
artikel
|
| 39 |
Chemotherapy Administration
|
Haywood, Philip
|
|
2012
|
|
12 |
p. 1173-1186
|
artikel
|
| 40 |
Chemotherapy Administration
|
Haywood, Philip
|
|
|
|
12 |
p. 1173-1186
|
artikel
|
| 41 |
Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
|
Rege, Bhaskar
|
|
|
|
12 |
p. 1261-1263
|
artikel
|
| 42 |
Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”
|
Gandjour, Afschin
|
|
2014
|
|
12 |
p. 1245-1246
|
artikel
|
| 43 |
Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
|
Manning, Richard
|
|
|
|
12 |
p. 1373-1374
|
artikel
|
| 44 |
Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer
|
Alberts, Steven R.
|
|
2014
|
|
12 |
p. 1231-1243
|
artikel
|
| 45 |
Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments
|
Łaszewska, Agata
|
|
|
|
12 |
p. 1221-1234
|
artikel
|
| 46 |
Conceptualising ‘Benefits Beyond Health’ in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis
|
Engel, Lidia
|
|
|
|
12 |
p. 1383-1395
|
artikel
|
| 47 |
Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis
|
Soares, Marta O.
|
|
2012
|
|
12 |
p. 1101-1117
|
artikel
|
| 48 |
Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis
|
Soares, Marta O.
|
|
|
|
12 |
p. 1101-1117
|
artikel
|
| 49 |
Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
|
Hong, Dongzhe
|
|
|
|
12 |
p. 1553
|
artikel
|
| 50 |
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018
|
Kim, David D.
|
|
|
|
12 |
p. 1377
|
artikel
|
| 51 |
Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
|
Bounthavong, Mark
|
|
2018
|
|
12 |
p. 1463-1473
|
artikel
|
| 52 |
Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection
|
Hung, Hui-Fang
|
|
2011
|
|
12 |
p. 1063-1073
|
artikel
|
| 53 |
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
|
Keeney, Edna
|
|
|
|
12 |
p. 1207-1220
|
artikel
|
| 54 |
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
|
Barbier, Michaela Carla
|
|
|
|
12 |
p. 1641-1655
|
artikel
|
| 55 |
Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
|
Garattini, Livio
|
|
2015
|
|
12 |
p. 1241-1244
|
artikel
|
| 56 |
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective
|
Qu, Tingting
|
|
|
|
12 |
p. 1247-1259
|
artikel
|
| 57 |
Cost Effectiveness of Falls and Injury Prevention Strategies for Older Adults Living in Residential Aged Care Facilities
|
Church, Jody L.
|
|
2015
|
|
12 |
p. 1301-1310
|
artikel
|
| 58 |
Cost Effectiveness of Herpes Zoster Vaccine in Canada
|
Najafzadeh, Mehdi
|
|
2009
|
|
12 |
p. 991-1004
|
artikel
|
| 59 |
Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens
|
Teigen, David
|
|
|
|
12 |
p. 1603-1615
|
artikel
|
| 60 |
Cost Effectiveness of Medication Adherence-Enhancing Interventions: A Systematic Review of Trial-Based Economic Evaluations
|
Oberjé, Edwin J. M.
|
|
2013
|
|
12 |
p. 1155-1168
|
artikel
|
| 61 |
Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis
|
Lu, Lanting
|
|
2012
|
|
12 |
p. 1157-1171
|
artikel
|
| 62 |
Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis
|
Lu, Lanting
|
|
|
|
12 |
p. 1157-1171
|
artikel
|
| 63 |
Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review
|
Saokaew, Surasak
|
|
2016
|
|
12 |
p. 1211-1225
|
artikel
|
| 64 |
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
|
Kim, Yun-Kyung
|
|
2018
|
|
12 |
p. 1475-1490
|
artikel
|
| 65 |
Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
|
Gutzwiller, Florian S.
|
|
2015
|
|
12 |
p. 1311-1324
|
artikel
|
| 66 |
Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice
|
Elliott, Rachel A.
|
|
2017
|
|
12 |
p. 1237-1255
|
artikel
|
| 67 |
Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective
|
Dakin, Helen
|
|
2011
|
|
12 |
p. 1075-1091
|
artikel
|
| 68 |
Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups
|
Mital, Shweta
|
|
|
|
12 |
p. 1359-1372
|
artikel
|
| 69 |
Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
|
Dong, Xinyue
|
|
|
|
12 |
p. 1187-1205
|
artikel
|
| 70 |
Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis
|
Gaujoux-Viala, Cécile
|
|
2012
|
|
12 |
p. 1145-1156
|
artikel
|
| 71 |
Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis
|
Gaujoux-Viala, Cécile
|
|
|
|
12 |
p. 1145-1156
|
artikel
|
| 72 |
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China
|
Tian, Lei
|
|
|
|
12 |
p. 1345-1358
|
artikel
|
| 73 |
Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review
|
Fu, Shuangshuang
|
|
|
|
12 |
p. 1421-1449
|
artikel
|
| 74 |
Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis
|
Spalding, James R.
|
|
2006
|
|
12 |
p. 1221-1232
|
artikel
|
| 75 |
Cost of Illness: An Ongoing Battle Worth Fighting
|
Greenberg, Paul E.
|
|
2014
|
|
12 |
p. 1151-1152
|
artikel
|
| 76 |
Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model
|
Dolk, Christiaan
|
|
2016
|
|
12 |
p. 1299-1308
|
artikel
|
| 77 |
Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?
|
Karnon, Jonathan
|
|
2015
|
|
12 |
p. 1281-1288
|
artikel
|
| 78 |
Could or Should We Use MCDA in the French HTA Process?
|
Ghabri, Salah
|
|
|
|
12 |
p. 1417-1419
|
artikel
|
| 79 |
Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice
|
O’Mahony, James F.
|
|
2015
|
|
12 |
p. 1255-1268
|
artikel
|
| 80 |
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation
|
Gal, Peter
|
|
|
|
12 |
p. 1629-1639
|
artikel
|
| 81 |
Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues
|
Danzon, Patricia M.
|
|
2018
|
|
12 |
p. 1395-1405
|
artikel
|
| 82 |
Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies
|
Birks, Stuart
|
|
2006
|
|
12 |
p. 1273-1274
|
artikel
|
| 83 |
Do Pharmacogenomic Tests Provide Value to Policy Makers?
|
Shih, Ya-Chen Tina
|
|
2006
|
|
12 |
p. 1173-1177
|
artikel
|
| 84 |
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
|
Simons, Martijn J. H. G.
|
|
|
|
12 |
p. 1429-1442
|
artikel
|
| 85 |
Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review
|
van der Pol, Simon
|
|
|
|
12 |
p. 1411-1427
|
artikel
|
| 86 |
Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease
|
Younossi, Zobair M.
|
|
2015
|
|
12 |
p. 1245-1253
|
artikel
|
| 87 |
Economic Aspects of Severe Sepsis
|
Burchardi, Hilmar
|
|
|
|
12 |
p. 793-813
|
artikel
|
| 88 |
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature
|
Albaba, Hamzeh
|
|
2017
|
|
12 |
p. 1195-1209
|
artikel
|
| 89 |
Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety
|
Najafzadeh, Mehdi
|
|
2017
|
|
12 |
p. 1297-1310
|
artikel
|
| 90 |
Economic Evidence at the Local Level
|
Gool, Kees van
|
|
2007
|
|
12 |
p. 1055-1062
|
artikel
|
| 91 |
Economic Implications of Endometriosis: A Review
|
Darbà, Josep
|
|
|
|
12 |
p. 1143-1158
|
artikel
|
| 92 |
Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
|
Sugrue, Daniel M.
|
|
|
|
12 |
p. 1451-1468
|
artikel
|
| 93 |
Efficiency of the EmERGE Pathway of Care in Five European HIV Centres
|
Beck, Eduard J.
|
|
|
|
12 |
p. 1235-1246
|
artikel
|
| 94 |
Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
|
Bentley, Anthony
|
|
2013
|
|
12 |
p. 1185-1186
|
artikel
|
| 95 |
Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK
|
Benedict, Á
|
|
2011
|
|
12 |
p. 1014
|
artikel
|
| 96 |
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework
|
Jiao, Boshen
|
|
|
|
12 |
p. 1617-1627
|
artikel
|
| 97 |
Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Grimm, Sabine E.
|
|
|
|
12 |
p. 1397-1410
|
artikel
|
| 98 |
Generic Health-Related Quality-of-Life Assessment in Children and Adolescents
|
Ravens-Sieberer, Ulrike
|
|
2006
|
|
12 |
p. 1199-1220
|
artikel
|
| 99 |
Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries
|
Rand, Leah Z.
|
|
|
|
12 |
p. 1131-1142
|
artikel
|
| 100 |
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations
|
Mukherjee, Kumar
|
|
|
|
12 |
p. 1589-1601
|
artikel
|
| 101 |
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting
|
van der Pol, Simon
|
|
|
|
12 |
p. 1355-1363
|
artikel
|
| 102 |
How to Include Informal Care in Economic Evaluations
|
Hoefman, Renske J.
|
|
2013
|
|
12 |
p. 1105-1119
|
artikel
|
| 103 |
Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets
|
Augestad, Liv Ariane
|
|
2012
|
|
12 |
p. 1203-1214
|
artikel
|
| 104 |
Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets
|
Augestad, Liv Ariane
|
|
|
|
12 |
p. 1203-1214
|
artikel
|
| 105 |
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach
|
Ochalek, Jessica
|
|
|
|
12 |
p. 1319-1331
|
artikel
|
| 106 |
Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence
|
Giannopoulou, Christina
|
|
2015
|
|
12 |
p. 1269-1279
|
artikel
|
| 107 |
Letter From the Commissioner’s Office at the US FDA
|
Vernon, John A.
|
|
2006
|
|
12 |
p. 1179
|
artikel
|
| 108 |
Management and Prevention of Diabetic Foot Ulcers and Infections
|
Chow, Ivy
|
|
2008
|
|
12 |
p. 1019-1035
|
artikel
|
| 109 |
Measuring US Pharmaceutical Industry R&D Spending
|
Golec, Joseph
|
|
2008
|
|
12 |
p. 1005-1017
|
artikel
|
| 110 |
Modelling Spillover Effects on Informal Carers: The Carer QALY Trap
|
Mott, David J.
|
|
|
|
12 |
p. 1557-1561
|
artikel
|
| 111 |
Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease
|
Dams, Judith
|
|
2011
|
|
12 |
p. 1025-1049
|
artikel
|
| 112 |
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
|
Gibson, Eddie
|
|
2017
|
|
12 |
p. 1257-1270
|
artikel
|
| 113 |
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
|
Mestre-Ferrandiz, Jorge
|
|
2018
|
|
12 |
p. 1407-1420
|
artikel
|
| 114 |
NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors
|
Getsios, Denis
|
|
2007
|
|
12 |
p. 997-1006
|
artikel
|
| 115 |
Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases
|
Miller, Paul S. J.
|
|
2016
|
|
12 |
p. 1277-1297
|
artikel
|
| 116 |
Objectivity and Equity: Clarity Required. A Response to Hill and Olson
|
Paulden, Mike
|
|
2014
|
|
12 |
p. 1249-1250
|
artikel
|
| 117 |
Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events
|
Heeg, Bart
|
|
2007
|
|
12 |
p. 1063-1082
|
artikel
|
| 118 |
Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort
|
Laxy, Michael
|
|
|
|
12 |
p. 1485-1494
|
artikel
|
| 119 |
Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models
|
Hatswell, Anthony J.
|
|
2018
|
|
12 |
p. 1421-1426
|
artikel
|
| 120 |
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Büyükkaramikli, Nasuh C.
|
|
2017
|
|
12 |
p. 1211-1221
|
artikel
|
| 121 |
Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies
|
Angelis, Aris
|
|
|
|
12 |
p. 1297-1308
|
artikel
|
| 122 |
Recombinant Factor VIIa (Eptacog Alfa)
|
Lyseng-Williamson, Katherine A.
|
|
2007
|
|
12 |
p. 1007-1029
|
artikel
|
| 123 |
Recurrent genital herpes treatments and their impact on quality of life
|
Brentjens, Mathijs H.
|
|
|
|
12 |
p. 853-863
|
artikel
|
| 124 |
Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
|
Padula, William V.
|
|
|
|
12 |
p. 1375-1376
|
artikel
|
| 125 |
Response to Comment on “An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
|
Piena, Marjanne A.
|
|
|
|
12 |
p. 1265-1267
|
artikel
|
| 126 |
Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data
|
Shih, Ya-Chen Tina
|
|
|
|
12 |
p. 1495-1507
|
artikel
|
| 127 |
Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal
|
Latimer, Nicholas R.
|
|
2014
|
|
12 |
p. 1171-1183
|
artikel
|
| 128 |
Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Bermejo, Iñigo
|
|
2018
|
|
12 |
p. 1427-1437
|
artikel
|
| 129 |
Search MEDLINE for Economic Evaluations: Tips to Translate an OVID Strategy into a PubMed One
|
Neyt, Mattias
|
|
2013
|
|
12 |
p. 1087-1090
|
artikel
|
| 130 |
Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer?
|
Connelly, Luke B.
|
|
|
|
12 |
p. 1289-1295
|
artikel
|
| 131 |
The Authors’ Reply
|
Bos, J. M.
|
|
2006
|
|
12 |
p. 1275-1276
|
artikel
|
| 132 |
The Carer QALY Trap and Altruism in Economic Evaluations
|
Tilford, J. Mick
|
|
|
|
12 |
p. 1553-1555
|
artikel
|
| 133 |
The economics of follow-on drug research and development: Trends in entry rates and the timing of development — The authors’ reply
|
DiMasi, Joseph A.
|
|
2005
|
|
12 |
p. 1193-1202
|
artikel
|
| 134 |
The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review
|
Sonntag, Michael
|
|
2013
|
|
12 |
p. 1131-1154
|
artikel
|
| 135 |
The Future of Precision Medicine: Potential Impacts for Health Technology Assessment
|
Love-Koh, James
|
|
2018
|
|
12 |
p. 1439-1451
|
artikel
|
| 136 |
The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
|
Grimm, Sabine Elisabeth
|
|
2017
|
|
12 |
p. 1287-1296
|
artikel
|
| 137 |
The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review
|
Wissinger, Erika
|
|
2014
|
|
12 |
p. 1213-1229
|
artikel
|
| 138 |
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
|
Ferrario, Alessandra
|
|
2017
|
|
12 |
p. 1271-1285
|
artikel
|
| 139 |
The Pharmacoeconomic Evaluation Process in Ireland
|
McCullagh, Laura
|
|
2016
|
|
12 |
p. 1267-1276
|
artikel
|
| 140 |
The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?
|
Whitehurst, David G. T.
|
|
|
|
12 |
p. 1283-1288
|
artikel
|
| 141 |
The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments
|
Antonanzas, Fernando
|
|
|
|
12 |
p. 1469-1483
|
artikel
|
| 142 |
The Value of Medicines: A Crucial but Vague Concept
|
Antoñanzas, Fernando
|
|
2016
|
|
12 |
p. 1227-1239
|
artikel
|
| 143 |
Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence
|
Norum, Jan
|
|
2017
|
|
12 |
p. 1223-1236
|
artikel
|
| 144 |
Understanding and Identifying Key Issues with the Involvement of Clinicians in the Development of Decision-Analytic Model Structures: A Qualitative Study
|
Husbands, Samantha
|
|
2018
|
|
12 |
p. 1453-1462
|
artikel
|
| 145 |
Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles
|
Wang, Ching-Yu
|
|
|
|
12 |
p. 1333-1343
|
artikel
|
| 146 |
Using Best–Worst Scaling to Investigate Preferences in Health Care
|
Cheung, Kei Long
|
|
2016
|
|
12 |
p. 1195-1209
|
artikel
|
| 147 |
Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease
|
Catt, Heather
|
|
|
|
12 |
p. 1509-1523
|
artikel
|
| 148 |
Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment
|
Wetering, Liesbet van de
|
|
2015
|
|
12 |
p. 1289-1300
|
artikel
|
| 149 |
Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Rafia, Rachid
|
|
2016
|
|
12 |
p. 1241-1253
|
artikel
|
| 150 |
Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal
|
Beale, Sophie
|
|
2013
|
|
12 |
p. 1121-1129
|
artikel
|
| 151 |
Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal
|
Farmer, Caroline
|
|
|
|
12 |
p. 1309-1318
|
artikel
|
| 152 |
What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK
|
Morrell, Liz
|
|
|
|
12 |
p. 1443-1454
|
artikel
|
| 153 |
What’s Good and Bad About Contraceptive Products?
|
Knox, Stephanie A.
|
|
2012
|
|
12 |
p. 1187-1202
|
artikel
|
| 154 |
What’s Good and Bad About Contraceptive Products?
|
Knox, Stephanie A.
|
|
|
|
12 |
p. 1187-1202
|
artikel
|
| 155 |
When NICE Says No!
|
Haycox, Alan
|
|
2007
|
|
12 |
p. 995-996
|
artikel
|
| 156 |
Why the Gap in Evaluating the Social Constructs and the Value of Medicines?
|
McRae, Jacquelyn
|
|
|
|
12 |
p. 1365-1372
|
artikel
|
| 157 |
Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
|
Lieu, Tracy A.
|
|
2009
|
|
12 |
p. 1005-1016
|
artikel
|
Tijdschrift beschrijving